# Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

> **NCT05856630** · PHASE1 · UNKNOWN · sponsor: **Luye Pharma Group Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Goserelin Acetate Sustained-Release Microspheres for Injection
- **DRUG:** Zoladex 10.8 MG Drug Implant

## Key facts

- **NCT ID:** NCT05856630
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05856630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05856630, "Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05856630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*